Nektar Therapeutics is seeking an experienced pain marketing partner to bring its first-in-class mu-opioid agonist NKTR-181 to market after a positive Phase III data readout. CEO Howard Robin detailed regulatory and partnering plans for the drug in a conference call March 20.
Nektar Turns Up The Heat On Partnering Talks For NKTR-181
The company reported positive Phase III efficacy data on the first-in-class mu-opioid agonist molecule designed to provide pain relief without the euphoria that leads to addiction with standard opioids.
